INDP
Indaptus Therapeutics, Inc. Common Stock
stockNASDAQ
the indaptus goal is simple: to cure disease with the ability to harness both the body's innate and adaptive immune responses, we believe we are uniquely positioned to revolutionize the treatment of cancer and certain infectious diseases. building on the observation that tumor regression can occur in the setting of bacterial infection, we have developed a proprietary platform that exploits bacteria's natural ability to activate both innate and adaptive cellular immune pathways. leveraging our novel insights into the levels and ratios of activating signals needed to safely elicit a broad immune response, we are creating and advancing a pipeline of proprietary, attenuated and killed non-pathogenic gram-negative bacterial candidates designed to be widely accessible, with broad anti-tumor and anti-viral activity.
| Period | Price | Date | Change | Beta |
|---|---|---|---|---|
| 1W | 2.85 | 2026-09-29 | -8.95% | 31.234 |
| 1M | 1.85 | 2026-09-08 | +40.27% | 1.534 |
| 3M | 2.85 | 2026-07-06 | -8.95% | -2.715 |
| 6M | 1.75 | 2026-04-06 | +48.29% | 0.500 |
| 1Y | 3.19 | 2025-10-06 | -18.65% | 1.865 |
| 2Y | 33.04 | 2024-10-07 | -92.15% | — |
| 5Y | 201.32 | 2021-10-06 | -98.71% | 1.102 |
Indaptus Therapeutics, Inc. Common Stock (NASDAQ:INDP) stock price today is $2.60, and today's volume is 253,796. INDP is up 3.386% today. The 30 day average volume is 1.17M. INDP market cap is $345.76M with 133.24M shares outstanding.